Navigation Links
Six Scientists Receive Awards for Contributions to Alzheimer's Disease Research
Date:7/13/2009

t have provided the most current information on the rates of Alzheimer's and other age-related disorders among African-American, Caribbean Hispanic and Caucasian elderly. His research focuses on Alzheimer's disease causes and risk factors, and their often complex interactions, with special emphasis on diverse communities.

The 2009 Khalid Iqbal Lifetime Achievement Award was awarded to Virginia M.-Y. Lee, Ph.D., M.B.A., director of the Center for Neurodegenerative Disease Research at the University of Pennsylvania, School of Medicine. Dr. Lee's research focus includes determining the genesis and roles of various normal and abnormal brain proteins (amyloid, tau, etc.) thought to be the keys to the cause and progression of numerous brain diseases, including Alzheimer's.

The 2009 Bengt Winblad Lifetime Achievement Award was awarded to Martin Rossor, M.D., head of the Division of Neurology and Director of the Dementia Research Centre at the UCL Institute of Neurology and the NationalHospital for Neurology and Neurosurgery, Queen Square, London. Dr Rossor's research includes studying familial Alzheimer's disease and familial frontotemporal lobar degeneration. Longitudinal studies of at risk individuals from affected families has helped identify the first clinical and imaging changes that signal the onset of disease.

Zaven Khachaturian Award

At ICAD 2009, William R. Markesbery, M.D., was recipient of the 2009 Zaven Khachaturian Award. This award, named in honor of Zaven Khachaturian, PhD, consultant, lecturer and author, recognizes an individual whose compelling vision, selfless dedication and extraordinary achievement has significantly advanced the field of Alzheimer science.

Dr. Markesbery is professor of Pathology and Neurology at the University of Kentucky, College of Medicine, and director of the Sanders-BrownCenter on Agi
'/>"/>

SOURCE Alzheimer's Association
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2009)...ill provides for an unprecedented expansion of fed...if it is not for preserving and protecting human l...ed." Charmaine Yoest ,, WASHINGTON, Nov. 21 ...fe Action President and CEO Dr. Charmaine Yoest re...ng the following statement: ,, "This was a pro...
(Date:11/21/2009)... NH based medical credentialing software company... form a partnerhsip with Amerinet, Inc., the leadi... will help to transform quality care within the he...) November 21, 2009 -- ISG Group, LLC, doing busin...ement with Amerinet Inc., a leading national healt...
(Date:11/21/2009)... Linwood Group ask whether there is a secret to ... London, UK (PRWEB) Novemb...o one in three of the adult UK population drinking...ohol-related liver disease*, it is hardly a surpri...ation programmes and residential centres for help....
(Date:11/20/2009)...., Nov. 20 Following a recall by U...moved from sale Shedd,s Country Crock ® Side ...untry Crock ® Side Dishes DELUXE Four Cheese ..., The following code dates and UPCs are affected: ...LUXE Cheddar Broccoli Rice 21 oz, UPC 027400218316...
(Date:11/20/2009)..., Israel, November 20 Ca...p://www.CVSLMEDICAL.COM , a leading,developer of a...nnounced that,the company,s Board of Directors has..., Canada and the Far East for its proprietary next...ll angioplasty (PCTA) procedures. , Cardi...
Breaking Medicine News(10 mins):Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2
...tients to be remotely monitored through XTend,s Di..., SUN VALLEY, Calif., Feb. 14 XTend Medical,Corp...mpany has begun a,remote diabetic monitoring progr...emotely monitor diabetic patients through the XTen...
...nvestments Totaled Approximately $2.2 Billion, Ven...o Range between $2.75 ...S EIGHT PERCENT TO $0.5125 PER SHARE, LOUISVILLE,...d common share rose ten percent to,$2.69, compared...
...ferers Can Enjoy a Romantic Valentine,s Day With ...LE, Feb. 13 , WHO: The 60 million Americans... don,t have to worry about a painful sore deraili... adhesive patch, has been shown in a peer-re...
...exico, among the choices for 2008, SEATTLE, Feb. ...lcanoes of Mexico" -- highlights the 2008 Climb to... Cancer Research Center., The 11th annual Climb h...,343 feet). Both trips will be led by,professional...
...3 Matrixx Initiatives, Inc.,(Nasdaq: MTXX ), an ...and,markets products that provide consumers with "...on Wednesday February 20, 2008, at the Roth,Capita... http://www.matrixxinc.com . Interested parties,sh...
...Feb. 13 Valentine,s Day is,not just for lovers. T...ers, St. Valentine, takes on greater meaning when ...sy -- a common neurological condition that,causes ...Valentine is connected to epilepsy because,the nam...
Other Medicine News:Health News:XTend Medical (XMDC) Begins Remote Diabetic Telehealth Program 2Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 2Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 3Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 4Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 5Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 6Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 7Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 8Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 9Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 10Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 11Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 12Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 13Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 14Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 15Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 16Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 17Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 18Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 19Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 20Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 21Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 22Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 23Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 24Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 25Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 26Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 27Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 28Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 29Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 30Health News:Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69 31Health News:Pucker Up Without the Pain 2Health News:Climb to Fight Breast Cancer Offers Peaks for Every Skill Level 2Health News:Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference 2
(Date:11/20/2009)...-- ,, Reportlinker.com announces that a new mar... ,, Global Markets for Breast Biopsy Devices 2...Global-Markets-for-Breast-Biopsy-Devices-2009.html...ampaign=prnewswire ,, The global markets for ...ore needle market and vacuum assisted breast biops...
(Date:11/20/2009)...tCall/ -- Cyberonics, Inc. (Nasdaq: CYBX ) today ...utive Officer, and Greg Browne, Chief Financial Of...ay Health Care Conference in New York on Wednesday...e session and webcast will be audio only and no fo... host a webcast of the presentation live and by re...
(Date:11/19/2009).../ -- Warner Chilcott plc (Nasdaq: WCRX ) today an...condary offering of 20,000,000 of its ordinary sha... The selling shareholders include funds affiliated... J.P. Morgan Partners (advised by CCMP Capital) an...itutional investors and members of the Company,s s...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Placental precursor stem cells require testosterone free environment to survive 10574 1Placental precursor stem cells require testosterone free environment to survive 10574 2American Physiological Society endorses report on random source dogs and cats 10569 1American Physiological Society endorses report on random source dogs and cats 10569 2American Physiological Society endorses report on random source dogs and cats 10569 3The Breema Center Offers Bodywork Mini Sessions and Demonstrations at the San Francisco Green Festival 60315 1The Breema Center Offers Bodywork Mini Sessions and Demonstrations at the San Francisco Green Festival 60315 2
...t from,Schering-Plough, Roche today affirmed the v...ination with ribavirin as the market-leading,treat...States and globally.,Despite clear biases in the d...d patients taking Peg-Intron(TM) (peginterferon al...reduction protocol - the study results have,shown ...
...ay, SOUTH SAN FRANCISCO, Calif., Jan. 14 Cell,Ge...the Independent Data,Monitoring Committee (IDMC) f...cal trials of GVAX immunotherapy for prostate canc...nd has recommended that the study continue.,This e...mine whether the,study should continue to completi...
Other Medicine Technology:Roche responds to announcement of 'IDEAL' hepatitis C trial results 2Roche responds to announcement of 'IDEAL' hepatitis C trial results 3Roche responds to announcement of 'IDEAL' hepatitis C trial results 4Roche responds to announcement of 'IDEAL' hepatitis C trial results 5Roche responds to announcement of 'IDEAL' hepatitis C trial results 6Roche responds to announcement of 'IDEAL' hepatitis C trial results 7Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer 2Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer 3Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer 4
Aaron 800-EU
Sabre 180, 100V, 50Hz/60Hz
Sabre 2400, 240V, 50Hz
Sabre 2400, 110V, 60Hz
Medicine Products: